26th Nov 2015 10:10
LONDON (Alliance News) - 4D Pharma PLC on Thursday said it has identified a live biotherapeutic candidate that has shown efficacy in pre-clinical models of breast and lung cancers, using its MicroRx platform.
MicroRx is a platform for the discovery of novel live biotherapeutics. To date, 4D has been focused on identifying autoimmune, respiratory and central nervous system therapies using the platform, and for the past six months has focused part of the work on oncology, leading it to identify an orally administered live biotherapeutic candidate that has produced good results in pre-clinical models of breast and lung cancers.
4D said it will accelerate the cancer programme further towards the clinic, aiming to have it ready for testing in patients in 12 months. It also will target the MicroRx platform towards other cancers.
"We believe the work we have completed over the last six months may open the way for the development of a completely new class of cancer therapeutics," Chairman Dave Norwood said in a statement.
"If, as we believe, we can demonstrate a favourable safety and efficacy profile, the work 4D has achieved could be a significant step forward in the treatment of cancer," he added.
Shares in 4D Pharma were trading up 0.6% at 795.00 pence Thursday morning.
By Karolina Kaminska; [email protected] @KarolinaAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
DDDD.L